ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Patient Harm—Including One Death—Cited As Faculty Challenges MD Anderson Leadership

September 20, 2013

DCT Adopts New Unsolicited Contract Review Procedures

May 21, 1976

Avastin Improves PFS In Advanced Breast Cancer

April 29, 2005

NCI Plans Trial Of Finasteride In Prostate Cancer

January 24, 1992

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

November 5, 2004

ODAC Votes for Marqibo Accelerated Approval

March 30, 2012